Status:

COMPLETED

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Healthy Participants

Idiopathic Pulmonary Fibrosis (IPF)

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel LPA1 positron emission tomography (PET) ligand 18F-BMS-986327 in healthy participan...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • All Participants:
  • · Body mass index of 18.0 to 34.0 kg/m\^2, inclusive, and body weight ≥ 50 kg
  • Healthy Participants:
  • Male and female healthy volunteers ages 18 or age or older
  • No clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs) and clinical laboratory determinations
  • Idiopathic Pulmonary Fibrosis (IPF) Participants:
  • Male and female participants aged 40 to 90 years
  • Diagnosis of IPF less than 6 years before randomization
  • Have no features supporting an alternative diagnosis on transbronchial biopsy, bronchoalveolar lavage or surgical lung biopsy
  • Exclusion Criteria (all participants):
  • Severe motor problems that prevent the ability to lie still for PET imaging procedure
  • Significant acute or chronic medical illness in the opinion of the investigator in consultation with the BMS Medical Monitor, could jeopardize the subject's safety, tolerability, or pharmacokinetics of 18F-BMS-986327
  • Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug
  • Any major surgery within 4 weeks of study drug administration
  • Other protocol-defined criteria apply

Exclusion

    Key Trial Info

    Start Date :

    October 1 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 12 2022

    Estimated Enrollment :

    14 Patients enrolled

    Trial Details

    Trial ID

    NCT04069143

    Start Date

    October 1 2019

    End Date

    July 12 2022

    Last Update

    March 7 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Local Institution - 0001

    New Haven, Connecticut, United States, 06520-8048